Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC3 | O15438 | 1/20 | 0.57 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.57 |
| ▸ | HMGCR | P04035 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | PDE6D | O43924 | 1/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | AKT1 | P31749 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4538441 | 0.91 | HMGCR (0.61) | ABCC3ABCC4HMGCRALDH1A1CYP3A4 | |
| SCHEMBL4150176 | 0.90 | ABCC3 (0.62) | ABCC3ABCC4HMGCRALDH1A1CYP3A4 | |
| SCHEMBL19474869 | 0.90 | ABCC3 (0.62) | ABCC3ABCC4HMGCRALDH1A1CYP3A4 | |
| SCHEMBL16401134 | 0.90 | ABCC3 (0.53) | ABCC3ABCC4HMGCRALDH1A1CYP3A4 | |
| SCHEMBL4538040 | 0.89 | ABCC3 (0.62) | ABCC3ABCC4HMGCRALDH1A1CYP3A4 | |
| SCHEMBL3887767 | 0.89 | HMGCR (0.59) | ABCC3ABCC4HMGCRALDH1A1CYP3A4 | |
| Zinc Ion SCHEMBL3884322 | 0.88 | ABCC3 (0.60) | ABCC3ABCC4HMGCRALDH1A1CYP3A4 | |
| SCHEMBL17635504 | 0.84 | HMGCR (0.67) | ABCC3ABCC4HMGCRALDH1A1CYP3A4 | |
| SCHEMBL6789988 | 0.82 | HMGCR (0.59) | ABCC3ABCC4HMGCRALDH1A1CYP3A4 | |
| SCHEMBL3885922 | 0.81 | HMGCR (0.62) | ABCC3ABCC4HMGCRALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655796-B2 | Process for the preparation of rosuvstatin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-02-02 | — | — | US | disclosed |
| WO-2009157014-A2 | A PROCESS FOR PREPARING HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2009-12-30 | — | — | WO | disclosed |
| US-7396927-B2 | Process for preparation of rosuvastatin calcium | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-07-08 | — | — | US | disclosed |
| WO-2007099561-A1 | PROCESS FOR PREPARING ROSUVASTATIN CALCIUM | CADILA HEALTHCARE LIMITED (IN) | 2007-09-07 | — | — | WO | disclosed |
| EP-1816126-A1 | Process for preparation of rosuvastatin calcium | Teva Pharmaceutical Industries Limited (IL) | 2007-08-08 | — | — | EP | disclosed |
| US-20070142418-A1 | Process for the preparation of rosuvastatin | TEVA PHARMACEUTICALS USA, INC. | 2007-06-21 | — | — | US | disclosed |
| US-7179916-B2 | Process for the preparation of rosuvastatin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-02-20 | — | — | US | disclosed |
| EP-1673351-A1 | A PROCESS FOR THE PREPARATION OF ROSUVASTATIN INVOLVING A TEMPO-MEDIATED OXIDATION STEP | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-06-28 | — | — | EP | disclosed |
| US-20060089501-A1 | Process for the preparation of rosuvastatin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-04-27 | — | — | US | disclosed |
| WO-2006017357-A1 | A PROCESS FOR THE PREPARATION OF ROSUVASTATIN INVOLVING A TEMPO-MEDIATED OXIDATION STEP | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-02-16 | — | — | WO | disclosed |
| EP-1425287-A4 | PROCESSES FOR PREPARING CALCIUM SALT FORMS OF STATINS | TEVA PHARMA (IL) | 2005-09-07 | — | — | EP | disclosed |
| US-20050080134-A1 | Process for preparation of rosuvastatin calcium | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-04-14 | — | — | US | disclosed |
| US-20040176615-A1 | Processes for preparing calcium salt forms of statins | NIDDAM-HILDESHEIM VALERIE (IL) | 2004-09-09 | — | — | US | disclosed |
| US-6777552-B2 | FROM AN ESTER DERIVATIVE OR PROTECTED ESTER DERIVATIVE OF THE STATIN BY USING CALCIUM HYDROXIDE | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2004-08-17 | — | — | US | disclosed |
| EP-1425287-A1 | PROCESSES FOR PREPARING CALCIUM SALT FORMS OF STATINS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-06-09 | — | — | EP | disclosed |
| US-20030114685-A1 | Processes for preparing calcium salt forms of statins | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2003-06-19 | — | — | US | disclosed |
| WO-2003016317-A1 | PROCESSES FOR PREPARING CALCIUM SALT FORMS OF STATINS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-02-27 | — | — | WO | disclosed |
| EP-0521471-B1 | Pyrimidine derivatives as HMG-CoA reductase inhibitors | SHIONOGI & CO (JP) | 2000-10-25 | — | — | EP | disclosed |
| US-5260440-A | Anticholesterol agents | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1993-11-09 | — | — | US | disclosed |
| EP-0521471-A1 | Pyrimidine derivatives as HMG-CoA reductase inhibitors | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089501-A1 | Process for the preparation of rosuvastatin | HMGCR, PCSK9, CETP | ABCC3 1573/4885ABCC4 1329/4885HMGCR 1/4885 |
| US-20040176615-A1 | Processes for preparing calcium salt forms of statins | HMGCR, PCSK9, LIPA | ABCC3 3434/4885ABCC4 2354/4885HMGCR 1/4885 |
| US-20050080134-A1 | Process for preparation of rosuvastatin calcium | HMGCR, PCSK9, ORAI1 | ABCC3 2671/4885ABCC4 2250/4885HMGCR 1/4885 |
| US-20070142418-A1 | Process for the preparation of rosuvastatin | HMGCR, PCSK9, FDPS | ABCC3 1352/4885ABCC4 1249/4885HMGCR 1/4885 |
| US-20030114685-A1 | Processes for preparing calcium salt forms of statins | HMGCR, PCSK9, LIPA | ABCC3 3434/4885ABCC4 2354/4885HMGCR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.